Compare Abeona Therapeutics Inc (ABEO) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Teucrium Soybean Fund — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while Teucrium Soybean Fund trades at $25.38. The key difference: Teucrium Soybean Fund is trading nearer its 52-week high, Abeona Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | SOYB | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $7.23 | $25.36 |
52-Week Low | $4.17 | $21.07 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SOYB trades at $25.24, up 3.27% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. Key support sits at $24 and resistance at $25. Recent news highlights potential tailwinds from China's $17 billion U.S. crop purchase pledge through 2028, which may benefit agricultural sectors including soybeans.
The stock's outlook is supported by positive technical momentum and favorable sector news, but investment appeal is tempered by a lack of available fundamental data on profitability and valuation. Risks include dependence on agricultural commodity cycles and trade policy stability. Investors should seek updated financials for a complete assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
